LUNDBECK WORLDWIDE Global About us Disease areas Investor Careers Media Patients Sustainability Explore our latest Lundbeck Magazine Read more Latest releases Sep 28, 2018 Takeda and Lundbeck submit New Drug Application (NDA) for vortioxetine... Aug 08, 2018 Lundbeck realized 14% growth in revenue (local currencies) and 83% growth in EPS View all releases Join Lundbeck 3 4 4 1 2 2 Current open positions Browse global vacancies Q2 2018 financial results Watch the investor presentation Download the Q2 2018 release Latest feature July 2018: Dr. Deborah Dunsire as new President and CEO Read more Corporate film Lundbeck is a global pharmaceutical company highly committed to improving the quality of life of people living with psychiatric and neurological disorders. Share price 396.3 DKK -2.461% Oct 04, 2018 16:59 (OMX: LUN) View share data Cookie Policy Page last modified 03 October 2018 H. Lundbeck A/S Ottiliavej 9 | 2500 | Valby | Denmark | Phone +45 3630 1311 | Fax +45 3630 1940 Sitemap | Contact us | Privacy policy and disclaimer Follow us on yYouTube tTwitter iLinkedIn

LUNDBECK WORLDWIDE Russia About Lundbeck Diseases Career Drugs Research Welcome to Lundbeck Russia To learn more Our corporate film Watch our video overview of Lundbeck's activities Jobs in Russia Vacancies Progress in thinking "Progress in Mind" is Lundbeck's commitment to raising awareness of the gravity of the burden of mental illness worldwide Learn more This page was last updated on August 1, 2017. Lundbeck Russia LLC 2nd Krutitskiy pereulok | 18 bldg 1 | 109044 | Moscow | Russian Federation Phone +7 495 380 3197 | Fax +7 495 380 3196 Sitemap | Our contacts | Responsibility